Table 2.

Results of the comparison of performance between the milestone method and the AUC method.

Trial	End-point	Median (months)		Milestone survival rate (%)		AUC (months)
		Experimental arm	Control arm	Experimental arm	Control arm	Experimental arm	Control arm
Gefitinib vs. paclitaxel + carboplatin in patients with metastatic non-small-cell lung cancer	Progression-free survival	9.1	5.4	65.8% at 8 months	25.9% at 8 months	11.3*	6.86*
Ipilimumab + dacarbazine vs. placebo + dacarbazine in patients with metastatic melanoma	Overall survival	11.2	9.1	18.2% at 5 years	8.8% at 5 years	23.1**	16.1**

^*The ratio of the two values of AUC (0.61) is not similar to the hazard ratio reported in the original trial (0.38; 95% CI, 0.26–0.56).

^**The ratio of the two values of AUC (0.70) is similar to the hazard ratio reported in the original trial (0.69; 95% CI, 0.57–0.84).

All survival information was drawn from the article by Hellman et al. (12); the values of median survival were those of the original trials.